Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK

Corient Private Wealth LLC purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 659,834 shares of the company’s stock, valued at approximately $7,489,000. Corient Private Wealth LLC owned 1.20% of Stoke Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Stoke Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Invesco Ltd. grew its position in Stoke Therapeutics by 117.0% in the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock valued at $174,000 after buying an additional 14,118 shares during the last quarter. Nuveen LLC acquired a new position in Stoke Therapeutics in the 1st quarter valued at $719,000. Russell Investments Group Ltd. acquired a new position in Stoke Therapeutics in the 1st quarter valued at $107,000. Finally, Fox Run Management L.L.C. purchased a new position in Stoke Therapeutics during the 1st quarter worth $92,000.

Stoke Therapeutics Trading Up 0.1%

STOK stock opened at $31.96 on Friday. The firm has a 50 day moving average of $30.23 and a 200-day moving average of $21.44. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 47.70 and a beta of 1.14. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 5,931 shares of Stoke Therapeutics stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32. Following the completion of the transaction, the insider owned 7,195 shares in the company, valued at approximately $185,055.40. The trade was a 45.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Adrian R. Krainer sold 40,472 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the completion of the sale, the director directly owned 364,246 shares in the company, valued at $9,827,357.08. This trade represents a 10.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 182,166 shares of company stock worth $5,136,957. Corporate insiders own 9.50% of the company’s stock.

Wall Street Analyst Weigh In

STOK has been the topic of a number of recent analyst reports. Needham & Company LLC boosted their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Wedbush boosted their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. HC Wainwright increased their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday, December 8th. Finally, Chardan Capital raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $34.78.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.